AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
299.17B
Market cap299.17B
Price-Earnings ratio
29.30
Price-Earnings ratio29.30
Dividend yield
1.63%
Dividend yield1.63%
Average volume
2.07M
Average volume2.07M
High today
$194.78
High today$194.78
Low today
$190.97
Low today$190.97
Open price
$193.84
Open price$193.84
Volume
2.07M
Volume2.07M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$122.48
52 Week low$122.48

Stock Snapshot

With a market cap of 299.17B, AstraZeneca(AZN) trades at $192.88. The stock has a price-to-earnings ratio of 29.30 and currently yields dividends of 1.6%.

On 2026-03-12, AstraZeneca(AZN) stock moved within a range of $190.97 to $194.78. With shares now at $192.88, the stock is trading +1.0% above its intraday low and -1.0% below the session's peak.

Trading volume for AstraZeneca(AZN) stock has reached 2.07M, versus its average volume of 2.07M.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

The stock's 52-week range extends from a low of $122.48 to a high of $212.71.

AZN News

TipRanks 7h
AstraZeneca’s DURGA-4 CAR-T Study Puts New Pressure on Multiple Myeloma Rivals

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The DURGA-4 study, formally titled “A Phase III Open-label, Randomised, Multicent...

TipRanks 7h
AstraZeneca Advances Pediatric Symbicort Device Study, Supporting Long Term Respiratory Strategy

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca study tracks how two versions of its asthma drug move through childre...

Benzinga 13h
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

British drugmaker AstraZeneca Plc (NYSE:AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ:ABVX) , following the company's dr...

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

TipRanks 14h
Abivax jumps 15% to $129.11 after report of exclusivity with AstraZeneca

05:45 EDT Abivax (ABVX) jumps 15% to $129.11 after report of exclusivity with AstraZeneca (AZN) Published first on TheFly – the ultimate source for real-time,...

TipRanks 14h
AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports

Abivax (ABVX) has granted AstraZeneca (AZN) an exclusive period through March 23 to access confidential information and formalize a potential takeover offer, La...

TipRanks 2d
AstraZeneca Wraps Real-World Lung Cancer Study, Sharpening Market Insight for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment...

TipRanks 2d
AstraZeneca Completes Key Japan Safety Study for Imfinzi/Imjudo in Liver Cancer

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study “Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / I...

TipRanks 3d
AstraZeneca Sets Digitally Enabled 2026 AGM with Key Governance and Capital Votes

The latest update is out from AstraZeneca ( (GB:AZN) ). AstraZeneca has published the notice and shareholders’ circular for its 2026 Annual General Meeting, wh...

TipRanks 3d
Keymed Gains US$45 Million Milestone as AstraZeneca Starts Phase III Trial of Core Cancer Drug

Keymed Biosciences, Inc. ( (HK:2162) ) has shared an update. Keymed Biosciences said partner AstraZeneca has begun a multi-center Phase III trial of CMG901, al...

TipRanks 4d
AstraZeneca, Daiichi Sankyo announce priority review for Enhertu sBLA

Daiichi Sankyo and AstraZeneca’s (AZN) supplemental biologics license application for Enhertu has been accepted and granted priority review in the U.S. for the...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.